

Elenco delle **pubblicazioni censite da Medline, in inglese:**

1. Mattavelli D, Miceli R, Radaelli S, Mattavelli F, Cantù G, Barisella M, Quattrone P, **Stacchiotti S**, Sangalli S, Casali PG, Gronchi A, and Fiore M. **Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution.** Ann Oncology 2013, in press.
2. **Stacchiotti S**, Tamborini, Lo Vullo S, Bozzi F, Messina A, Morosi C, Casale A, Crippa F, Conca E, Negri T, Palassini E, Marrari A, Palmerini E, Mariani L, Gronchi A, Pilotti S, Casali PG. **Phase 2 study on lapatinib in advanced EGFR-positive chordoma.** Ann Oncology 2013, in press.
3. ESMO / European Sarcoma Network Working Group **Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.** Ann Oncol. 2012 Oct;23 Suppl 7:vii92-9
4. ESMO / European Sarcoma Network Working Group. **Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.** Ann Oncol. 2012 Oct;23 Suppl 7:vii49-55.
5. ESMO / European Sarcoma Network Working Group. **Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.** Ann Oncol. 2012 Oct;23 Suppl 7:vii100-9.
6. **Stacchiotti S**, Dagrada G, Morosi C, Negri T, Romanini A, Pilotti S, Gronchi A, Casali PG. **Extraskeletal myxoid chondrosarcoma: tumor.** Clinical Sarcoma Research 2012; 2:22.
7. Gronchi A, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, **Stacchiotti S**, Ferrari S, Fiore M, Casali PG. **Quality of surgery and neoadjuvant combined therapy in the ISG_GEIS trial of soft tissue sarcomas of limbs and trunk wall.** Ann Oncol 2012, in press.
8. **Stacchiotti S**, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, Gronchi A, Dei Tos P, Morosi C, Messina A, Pilotti S, Casali PG. **Sunitinib in solitary fibrous tumor.** Ann Oncol 2012, in press.
9. **Stacchiotti S**, Verderio P, Messina A, Morosi C, Collini P, Llobart Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Casali P, Gronchi A. **Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy: an exploratory analysis on a Phase III trial.** Cancer 2012, in press.
10. Collini P, Negri T, Barisella M, **Stacchiotti S**, Palassini E, Pastorino U, Gronchi A, Casali PG, Pilotti S. **High-grade sarcomatous overgrowth in solitary fibrous tumor: a clinico-pathological study of 10 cases.** Am J Surg Path 2012, 36:1202-1215.
11. Colombo C, Miceli R, Collini P, Radaelli S, Palassini E, **Stacchiotti S**, Fiore M, Mariani L, Casali P, Gronchi A. **Leiomyosarcoma and sarcoma with myogenic differentiation: two different entities or two faces of the same disease?** Cancer, in press.
12. **Stacchiotti S**, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, Gronchi A, Amore P, Vinaccia V, Casali PG. **A phase II study on imatinib in advanced chordoma.** JCO 2012; 30:914-20
13. Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, **Stacchiotti S**, Dei Tos AP, De Paoli A, Longhi A, Poveda AM, Quagliuolo V, Comandone A, Casali PG, Picci P. **Short, Full-Dose Adjuvant Chemotherapy In High-Risk Adult Soft Tissue Sarcomas (STS): A Randomized Clinical Trial From The Italian Sarcoma Group (ISG) And The Spanish Sarcoma Group (GEIS).** JCO 2012; 30:850-6.
14. Gronchi A, Miceli M, Colombo C, **Stacchiotti S**, Collini P, Mariani L, Sangalli C, Radaelli S, Sanfilippo R, Fiore M, Casali PG. **Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas.** Ann Oncol; 23:1067-73.
15. Cassier PA, Gelderblom H, **Stacchiotti S**, Thomas D, Maki RG, Kroep JR, T van der Graaf W, Italiano A, Seddon B, Dômont J, Bompas E, Wagner AJ, Blay JY **Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular sinovitis.** Cancer 2012; 118:1649-55.
16. Cassier PA, Gelderblom H, **Stacchiotti S**, Thomas D, Maki RG, Kroep JR, T van der Graaf W, Italiano A, Seddon B, Dômont J, Bompas E, Wagner AJ, Blay JY **Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular sinovitis.** Cancer 2012; 118:1649-55.
17. Negri T, Brich S, Conca E, Bozzi F, Orsenigo M, **Stacchiotti S**, Alberghini M, Mauro V, Gronchi A, Dusio GF, Pelosi G, Picci P, Casali PG, Pierotti MA, Pilotti S. **Receptor Tyrosine Kinase Pathway Analysis Sheds Light on Similarities between Clear Cell Sarcoma and Metastatic Melanoma.** Genes, Chromosomes and Cancer, 2012; 51(2):111-26

18. **Stacchiotti S**, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, De Rosa P, Nuzzo A, Turano S, Morosi C, Dei Tos AP, Pilotti S, Casali PG. **Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network.** *Ann Oncol* 2012; 23(2):501-8.
19. **Stacchiotti S**, Casali PG. **Systemic therapy options for unresectable and metastatic chordomas.** *Curr Oncol Rep* 2011, 13: 323-30.
20. Gronchi A, Miceli R, Colombo C, Collini P, **Stacchiotti S**, Olmi P, Mariani L, Bertulli R, Fiore M, Casali PG. **Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution.** *Ann Oncol.* 2011, 22:1675-81.
21. **Stacchiotti S**, Negri T, Zaffaroni T, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, Gronchi A, Casali PG and Pilotti S. **Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.** *Ann Oncol* 2011, 22:1682-90.
22. **Stacchiotti S**, Pedeutour F, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, Gronchi A, Pilotti S and Casali PG. **Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.** *Int J Cancer*, 2011, 129:1761-72.
23. Grignani G, Palmerini E, **Stacchiotti S**, Boglione A, Ferraresi V, Frustaci S, Comandone A, Aliberti S, Casali PG, Ferrari S, Aglietta M. **A phase II trial of imatinib mesylate in relapsed non-resectable chondrosarcomas expressing platelet derived growth factor receptor-alpha or -beta: an Italian Sarcoma Group study.** *Cancer* 2011, 117:826-31.
24. Dileo P, Prici S, Tamborini E, Negri T, **Stacchiotti S**, Gronchi A, Posocco P, Laurini E, Coco P, Fumagalli E, Casali PG, Pilotti S. **Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study.** *Int J Cancer* 2011, 128:983-90.
25. Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, **Stacchiotti S**, Casali PG, Gronchi A. **Alveolar Soft Part Sarcoma: Clinical Presentation, Treatment, and Outcome in a Series of 33 Patients at a Single Institution.** *Ann Surg Oncol.* 2010, 17:3229-33.
26. **Stacchiotti S**, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG, Pilotti S. **Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.** *Mol Cancer Ther.* 2010; 9:1286-97.
27. Ardoino I, Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, Collini P, **Stacchiotti S**, Casali PG, Gronchi A. **Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma.** *Cancer* 2010, 116: 2429-36.
28. **Stacchiotti S**, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, Gronchi A, Casali PG. **Tumor response to sunitinib malate observed in clear cell sarcoma.** *Ann Oncol* 2010, 21:1130-1.
29. Tamborini E, Viridis E, Negri T, Orsenigo M, Brich S, Conca E, Gronchi A, **Stacchiotti S**, Manenti G, Casali PG, Pierotti MA and Pilotti S. **Analysis of receptor tyrosine kinase and downstream pathways in chordomas.** *Neuro Oncology* 2010, 12: 776-89.
30. Gronchi A, Lo Vullo S, Colombo C, Collini P, **Stacchiotti S**, Mariani L, Fiore M, Casali Paolo. **Extremity soft tissue sarcoma in a series of patients treated at a single institution: the local control directly impacts survival** *Annals of Surgery.* *Ann Surg* 2010; 251, 512-517.
31. **Stacchiotti S**, Casali PG, Salvatore Lo Vullo, Luigi Mariani, Elena Palassini, Mario Mercuri, Marco Alberghini, Silvana Pilotti, Lucciana Zanella, Alessandro Gronchi, and Piero Picci. **Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers.** *Ann Surg Oncol* 2010; 17, 211-219.
32. **Stacchiotti S**, Marrari A, Tamborini E, Palassini E, Viridis E, Messina A, Crippa F, Morosi C, Gronchi A, Pilotti S and Casali PG. **Response to imatinib plus sirolimus in advanced chordoma.** *Ann Oncol* 2009; 20:1886-94.
33. **Stacchiotti S**, Collini P, Messina A, Morosi A, Bertulli R, Dileo P, Piovesan C, Gronchi A, Casali PG. **Tumor response assessment in high grade soft tissue sarcomas (STS): a pilot study to assess the correlation between radiological and pathological response using both RECIST and Choi's criteria.** *Radiology*, 2009; 251:447-56.
34. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, **Stacchiotti S**, Pennacchioli E, Casali PG, Gronchi A. **Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).** *Eur J Surg Oncol*, 2009; 35:739-45
35. **Stacchiotti S**, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, Casali PG, Pilotti S. **Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma (ASPS).** *Clin Cancer Res*, 2009; 15:1096-104.

36. Gronchi A, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E, Mariani L, Casali PG. **Aggressive Surgical Policies in a Retrospectively Reviewed Single-Institution Case Series of Retroperitoneal Soft Tissue Sarcoma Patients.** J Clin Oncol, 2009; 27: 24-30.
37. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, **Stacchiotti S**, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG. **Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.** Lancet Oncol, 2007; 8:595-602.
38. Casali PG, **Stacchiotti S**, Sangalli C, Olmi P, Gronchi A. **Chordoma.** Curr Opin Oncol, 2007; 19: 367-70.
39. Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, **Stacchiotti S**, Ferrari A, Collini P, Lozza L, Mariani L, Casali PG, Gronchi A. **Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution.** Cancer, 2007; 109: 2522-31.
40. Tamborini E, Casieri P, Piselli F, Orsenigo M, Negri T, Piacenza C, **Stacchiotti S**, Gronchi A, Pastorino U, Pierotti MA, Pilotti S. **Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas.** J Pathol, 2007; 212: 227-235.
41. Negri T, Casieri P, Piselli F, Orsenigo M, Piacenza C, **Stacchiotti S**, Bidoli P, Casali PG, Pienotti MA, Tamborini E, Pilotti S. **Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.** Br J Cancer, 2007; 96: 180-181.
42. Manoukian S, Peissel B, Pensotti V, Barile M, Cortesi L, **Stacchiotti S**, Terenziani M, Barbera F, Pasquini G, Frigerio S, Pienotti MA, Radice P, Della Torre G. **Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families.** Eur J Cancer, 2007; 43: 601-606.
43. Ferrari A, Grosso F, **Stacchiotti S**, Meazza C, Zaffignani E, Marchianò A, Casanova M. **Response to Vinorelbine and low dose Cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor.** Pediatr Blood Cancer, 2007; 49(6):864-6.
44. Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, **Stacchiotti S**, Pastore E, Gronchi A, Perrone F, Carbone A, Pierotti MA, Casali PG, Pilotti S. **Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.** Clin Cancer Res, 2006; 12: 6920-8.
45. Grosso F, Dileo P, Sanfilippo R, **Stacchiotti S**, Bertulli R, Piovesan C, Jimeno J, D'Incalci M, Gescher A, Casali PG. **Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.** Eur J Cancer, 2006; 42: 1484-90.
46. Casali PG, Bertulli R, Fumagalli E, Coco P, Grosso F, **Stacchiotti S**. **Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors.** J Chemother, 2004;16 Suppl 4: 55-58.
47. Casali PG, Messina A, **Stacchiotti S**, Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R, Bertulli R, Colecchia M, Fumagalli E, Greco A, Grosso F, Olmi P, Pierotti MA, Pilotti S. **Imatinib mesylate in chordoma.** Cancer, 2004; 101: 2086-2097.
48. Gavazzi C, **Stacchiotti S**, Cavalletti R, Lodi R. **Confusion after antibiotics.** Lancet, 2001; 357: 1410.